Targeted Genetics Corporation
|
1100 Olive Way
Seattle, WA 98101
United States |
| Tel: |
1/206 623-7612 |
| URL: |
http://www.targen.com |
|
 |
| Primary Symbols & Exchanges: |
| TGEN - NASDAQ |
| - Berlin-Bremen Stock Exchange |
|
|
| Primary Industry: |
| Biotechnology |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Group's principal activities are to develop gene therapy products and technologies for the treatment of acquired and inherited diseases. The gene therapy products are designed to treat diseases by regulating cellular function at a genetic level. Gene therapeutics consists of a delivery vehicle called a vector and geneticmaterial. The role of the vector is to carry the genetic material into a target cell. Currently, the Group has ongoing preclinical product development activities in the areas of Inflammatory Arthritis, HIV/ AIDS Vaccine, Congestive Heart Failure, Huntington's disease, Hyperlipidemia, cystic fibrosis, hemophilia A, arthritis, cancer. The product candidates under clinical development program include tgAAC09 for the treatment of AIDS, tgAAC94 for Inflammatory Arthritis, SERCA2a for Congestive Heart Failure and htt siRNA for Huntington's disease. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Targeted Genetics Corporation
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
